Literature DB >> 32367591

Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation.

Xingquan Xu1,2, Rongliang Wang1,2, Rui Wu1,2, Wenjin Yan1,2, Tianshu Shi1,2, Qing Jiang1,2, Dongquan Shi1,2.   

Abstract

Bone loss is a severe complication of primary biliary cirrhosis (PBC). Trehalose was intermittently administered in bile duct-ligated (BDL) male rats, a PBC-related osteoporosis model, for 4 weeks to reduce osteoporosis. Femoral bones were assessed ex vivo by micro computed tomography (CT) and histomorphometry. The potential mechanisms related to the reduction of osteoporosis were explored by evaluating the effect of trehalose on osteoblast autophagy, osteogenesis, osteoclastogenesis, and ERK phosphorylation. The results demonstrated that trehalose reduced osteoporosis of BDL rats and decreased osteoblast-mediated osteoclast differentiation by enhancing osteoblast autophagy to regulate osteoprotegerin (OPG) secretion. Hydroxychloroquine (HCQ) increased the expression of OPG and OPG/receptor activator genes for nuclear factor-κB ligand (RANKL) ratio, and reduced osteoblast-mediated osteoclastogenesis by inhibiting autophagy flux and inducing autophagosome formation. Furthermore, trehalose increased the phosphorylation of ERK1/2 in MC3T3-E1 cells, and the ERK inhibitor PD98059 reversed the upregulation of OPG gene and reduction of trehalose-induced osteoclastogeneis. The treatment with HCQ markedly increased the ERK phosphorylation. The correlation between autophagosome formation and ERK phosphorylation was confirmed in autophagy proteins (ATG) 4B or ATG5-deficient cells. Thus, trehalose could decrease osteoblast-mediated osteoclastogenesis and reduce PBC-related bone loss by regulating ERK phosphorylation via autophagosome formation.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  ERK phosphorylation; autophagosomes; osteoclastogenesis; osteoporosis in PBC; trehalose

Year:  2020        PMID: 32367591     DOI: 10.1096/fj.201902528RRR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  5 in total

1.  A sustained-release Trametinib bio-multifunction hydrogel inhibits orthodontically induced inflammatory root resorption.

Authors:  Hang Yu; Zhina Wu; Xingfu Bao; Xiaoduo Tang; Junhu Zhang; Yi Zhang; Min Hu
Journal:  RSC Adv       Date:  2022-06-06       Impact factor: 4.036

2.  Gut Metabolite Urolithin A Inhibits Osteoclastogenesis and Senile Osteoporosis by Enhancing the Autophagy Capacity of Bone Marrow Macrophages.

Authors:  Huaqiang Tao; Yunxia Tao; Chen Yang; Wenming Li; Wei Zhang; Xueyan Li; Ye Gu; Yujing Hong; Huilin Yang; Yu Liu; Xing Yang; Dechun Geng
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

Review 3.  The Role of IL-35 in the Pathophysiological Processes of Liver Disease.

Authors:  Shuang Hu; Pan-Pan Lian; Ying Hu; Xing-Yu Zhu; Shao-Wei Jiang; Qiang Ma; Liang-Yun Li; Jun-Fa Yang; Li Yang; Hai-Yue Guo; Hong Zhou; Chen-Chen Yang; Xiao-Ming Meng; Jun Li; Hai-Wen Li; Tao Xu; Huan Zhou
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

4.  The effect of QiangGuYin on osteoporosis through the AKT/mTOR/autophagy signaling pathway mediated by CKIP-1.

Authors:  Yifeng Yuan; Jiangang Sun; Hang Zhou; Shen Wang; Caijian He; Tianpeng Chen; Mouhao Fang; Shaohua Li; Shifa Kang; Xiaosheng Huang; Binbin Tang; Bocheng Liang; Yingdelong Mao; Jianyou Li; Xiaolin Shi; Kang Liu
Journal:  Aging (Albany NY)       Date:  2022-01-24       Impact factor: 5.682

5.  Heterozygous LRP1 deficiency causes developmental dysplasia of the hip by impairing triradiate chondrocytes differentiation due to inhibition of autophagy.

Authors:  Wenjin Yan; Liming Zheng; Xingquan Xu; Zheng Hao; Yibo Zhang; Jun Lu; Ziying Sun; Jin Dai; Dongquan Shi; Baosheng Guo; Qing Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-06       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.